Phase 3Not yet recruiting
A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-OLE). (DAN-302)
An Open-label Extension Study to Assess the Long-term Safety and Efficacy of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-OLE).
- Sponsor
- Kardigan Inc. (Industry)
- Enrolment
- 211 planned
- Conditions
- Symptomatic genetic and familial dilated cardiomyopathy.; Dilated cardiomyopathy
- Interventions
- Danicamtiv
- Ages
- adults, older adults
- Registry
- CTIS2026-526139-20-00
Full record on the EU Clinical Trials Information System
From the registry
Main objective: To assess the long-term safety and tolerability of danicamtiv in participants with symptomatic genetic and familial Dilated Cardiomyopathy (DCM).
Primary outcomes
- Frequency and severity of treatment-emergent adverse events, adverse events of special interest, serious adverse events and disease-related events. Frequency of abnormal findings from physical examination, vital signs, 12-lead ECGs, and clinical laboratory assessments (including troponins).
History
Last registry update
Registered